Skip to content

Flavin mononucleotide-based biomimetic redox flow biosensor for rapid miRNA-21 detection in colorectal cancer diagnostics.

Dec 2026 · Analytica Chimica Acta · Vol 1426, pp. 346340 · 0 citations · 36 references
Medicine

Abstract

Detection of tumor biomarkers in serum and cellular samples is essential for early diagnosis and precision treatment of colorectal cancer, and miRNA-21 is well-established as a pivotal oncogenic biomarker for this malignancy. Conventional nucleic acid detection methods typically rely on complex enzymatic amplification and lengthy workflows, severely restricting their application in point-of-care clinical screening and long-term dynamic disease monitoring. In this work, a novel biomimetic redox flow biosensor based on flavin mononucleotide (FMN) is developed for rapid quantitative detection of miRNA-21, marking the first application of FMN as an electroactive tag for trace nucleic acid analysis. The sensing mechanism centers on Ti4+ as a multifunctional coordination bridge, which forms stable bonds simultaneously with phosphate moieties of FMN and the phosphate backbone of target miRNA-21. This multisite coordination strategy enables ultrahigh detection sensitivity without additional signal amplification procedures. The fabricated biosensor exhibits an excellent linear response for miRNA-21 detection across 1∼10000 pM, with a detection limit as low as 0.18 pM. It converts biological recognition events into distinguishable electrochemical signals within 1 h under mild conditions, and shows outstanding selectivity and anti-interference capability in complex biological matrices. Notably, the system supports real-time data viewing and storage via mobile terminals, enabling IoT-compatible personalized health management and long-term dynamic monitoring. This portable biosensor suits high-throughput clinical colorectal cancer screening, facilitating early clinical intervention and precise tumor treatment.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.